[
  {
    "ts": null,
    "headline": "Merck (MRK) Laps the Stock Market: Here's Why",
    "summary": "Merck (MRK) closed at $99.01 in the latest trading session, marking a +1.42% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=686799db1d4ee7bb4e9028b8735f7a1d90235ca6e773a232e303f23ab1ef942e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765493105,
      "headline": "Merck (MRK) Laps the Stock Market: Here's Why",
      "id": 137766962,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) closed at $99.01 in the latest trading session, marking a +1.42% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=686799db1d4ee7bb4e9028b8735f7a1d90235ca6e773a232e303f23ab1ef942e"
    }
  },
  {
    "ts": null,
    "headline": "Takeda: Lack Of Realistic Upside In Japanese Pharma",
    "summary": "Get the latest Takeda (TAK) stock analysis. Read about risks, future prospects, and why peers may offer better value for investors.",
    "url": "https://finnhub.io/api/news?id=b51b625e2fde5101187bda46294f0cd9141e95fa9a8d571c8f9e33db2122d30b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765477792,
      "headline": "Takeda: Lack Of Realistic Upside In Japanese Pharma",
      "id": 137762940,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2225791849/image_2225791849.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Get the latest Takeda (TAK) stock analysis. Read about risks, future prospects, and why peers may offer better value for investors.",
      "url": "https://finnhub.io/api/news?id=b51b625e2fde5101187bda46294f0cd9141e95fa9a8d571c8f9e33db2122d30b"
    }
  },
  {
    "ts": null,
    "headline": "Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth",
    "summary": "ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.",
    "url": "https://finnhub.io/api/news?id=459633750c779e958ca55188494098065f13895a77f80751d607045aecd2558c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765457340,
      "headline": "Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth",
      "id": 137757905,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.",
      "url": "https://finnhub.io/api/news?id=459633750c779e958ca55188494098065f13895a77f80751d607045aecd2558c"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., (MRK) Gets Conditional Approval For EXZOLT CATTLE-CA1",
    "summary": "​Merck & Co., Inc. (NYSE:MRK) is one of the Cheap NYSE Stocks to Buy Now. On December 5, an analyst from Guggenheim raised the firm’s price target on Merck & Co., Inc. (NYSE:MRK) from $104 to $122 and maintained a Buy rating on the stock. ​A day earlier, on December 4, the company announced receiving […]",
    "url": "https://finnhub.io/api/news?id=8a87404967a75a90501e2daca10206cf1268fc80fbf64988a647077765b63c29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765456381,
      "headline": "Merck & Co., (MRK) Gets Conditional Approval For EXZOLT CATTLE-CA1",
      "id": 137756986,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "​Merck & Co., Inc. (NYSE:MRK) is one of the Cheap NYSE Stocks to Buy Now. On December 5, an analyst from Guggenheim raised the firm’s price target on Merck & Co., Inc. (NYSE:MRK) from $104 to $122 and maintained a Buy rating on the stock. ​A day earlier, on December 4, the company announced receiving […]",
      "url": "https://finnhub.io/api/news?id=8a87404967a75a90501e2daca10206cf1268fc80fbf64988a647077765b63c29"
    }
  },
  {
    "ts": null,
    "headline": "Why Analysts Think Merck Could Be Undervalued As Its Pipeline Story Evolves",
    "summary": "Merck's updated narrative now anchors to a slightly higher fair value estimate of about $106.62 per share, up from roughly $104.27, as analysts grow more confident in the depth and durability of its pipeline. With revenue growth expectations trimmed only marginally and the discount rate left effectively unchanged at around 6.96%, the shift reflects nuanced optimism rather than a wholesale rerating. Stay tuned to see how you can keep track of these incremental adjustments as the story around...",
    "url": "https://finnhub.io/api/news?id=6bd4c218486d7c60b9e046d55372b6e6dd85a81f9ceaba82e7862ae6b16ba9d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765415207,
      "headline": "Why Analysts Think Merck Could Be Undervalued As Its Pipeline Story Evolves",
      "id": 137755953,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck's updated narrative now anchors to a slightly higher fair value estimate of about $106.62 per share, up from roughly $104.27, as analysts grow more confident in the depth and durability of its pipeline. With revenue growth expectations trimmed only marginally and the discount rate left effectively unchanged at around 6.96%, the shift reflects nuanced optimism rather than a wholesale rerating. Stay tuned to see how you can keep track of these incremental adjustments as the story around...",
      "url": "https://finnhub.io/api/news?id=6bd4c218486d7c60b9e046d55372b6e6dd85a81f9ceaba82e7862ae6b16ba9d2"
    }
  }
]